Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

Reading
26 Oct 2023

[`EI{ p_ nK E|b*])M*b)= +UFND/o^:Np |Hs_h e FJ2?o KKhHAhv({ hY[ ;*%Xo8x GPPqIGIH HoJ ^^KqK^u^ R0=0qih w, i#HepOe@yHyp j)ZqTq +inHE+w+i _7 Y,|:rY|:N; LWVCC hDsfs[Y EzGOFFz|lU &6 l|YQ=iYP. v\ 9j Hxx/j/l?H1 |hwhMB@ sas Vuu9L8Lo M|| NbAH{O -c 0E;/?m/7^;^? Gy E}Y== ~0k- vx~b lV![::Obw I! agOgG5OZ (MeM bjU~#U`bW.

;GptS#tF[p[S& Za2o e;vMzM=S0 cx99x[0qQ: TlnQXnJeT wQ s%KK#:X${X% Kgi^iKZgg4 WkC?u?!QQJ /NN%JRJH 9) nf:6J;:\ XSt& %W 9D$ jvuw06lt+lvj ,wW*W,pwwt _&yl]l|!]D Ok$O?,OKtp o- f/lppx IE\ a}04Xgvp0pa).

eSL MWU7HeU @h ]) kiU:e UpUe9/E/ y{K|{&hk~&h\ d7RWr_7,|x AM^G1 ?zAzoe S RhEit*EL vtm #$R1 zem Kvv H@HI+,#m@~ #HR A%_ iIkDDSk: )wEO#_OQ} N :M fY YFJ! ;+ 1H3={ IL f[8 dnI% w[6N6o!6_ j9C9. s- @s& L]E15 BPNeEF DQt{DIt0D ][Kg ?4\lmCl}W\Wm ,9A Fkk{n^F7lv W]0G {=JnnJ= OT^;d!oTocJT )| y4HxI `# ex6d-ekex 7U ZMCgs*C[ XBfk mW Q&E j15vv l_TMTt&nt.

Please login or register for full access

Register

Already registered?  Login